Category: Hiv aids

With a reported first-year list price exceeding $42,000, Sunlenca is a significant investment for heavily treatment-experienced adults with HIV. This sticker shock naturally prompts the question, 'How much is Sunlenca?' for patients, and the answer is complex, depending on a multitude of factors including insurance, financial assistance, and dosing schedules.

Tesamorelin, marketed under brand names like Egrifta WR, is not banned and remains an FDA-approved treatment for HIV-associated lipodystrophy. The persistent question of "Why was tesamorelin banned?" stems from regulatory events and confusion surrounding different formulations and international market applications. This article clarifies the drug's true regulatory history.

An undetectable viral load can be achieved in most people within six months of starting HIV treatment. However, the notion of stopping medication after achieving this milestone is a common misconception, leading many to ask: do you have to take Biktarvy forever? The answer for nearly all individuals is a definitive yes, as stopping medication carries severe health risks.

According to manufacturers and medical experts, there is no acceptable number of missed Biktarvy doses, as even a single missed pill carries risks that can affect the long-term efficacy of your HIV treatment. Maintaining strict adherence is the cornerstone of successful antiretroviral therapy (ART) to keep your viral load suppressed and prevent drug resistance.

While antiretroviral therapy (ART) has transformed HIV into a manageable, chronic condition for millions, it is still crucial to understand what are the negative effects of antiretroviral drugs. Most side effects are manageable and diminish over time, but some can be serious or impact a person's quality of life.

While modern antiretroviral therapy (ART) has significantly extended the lifespan of people living with HIV, studies show that older medications like tenofovir disoproxil fumarate (TDF) can contribute to kidney damage. This guide will explore the question of whether antiretroviral drugs cause kidney failure, outlining the specific risks associated with certain medications and advancements that have made treatment safer.

Nelfinavir, an antiretroviral medication approved by the FDA in 1997, is not an antibiotic but a protease inhibitor used in the treatment of human immunodeficiency virus (HIV). This distinction is crucial for understanding how the drug works and why it targets viral infections rather than bacterial ones.

First approved in 1987, the drug azidothymidine (AZT), now known as zidovudine, was the first medication to be made available for the treatment of HIV/AIDS, offering a glimmer of hope during a critical period of the epidemic. Its effectiveness hinges on its ability to inhibit a specific viral enzyme: HIV reverse transcriptase.

According to studies like the ADVANCE trial, individuals on regimens containing dolutegravir and tenofovir alafenamide (TAF) experience significantly greater weight gain than those on older treatments. The question of which antiretroviral causes weight gain is increasingly important as modern therapies improve health outcomes but present new metabolic challenges.

According to the National Institutes of Health, newer antiretroviral (ARV) regimens have significantly improved safety profiles compared to older drugs, with most side effects being mild and manageable. Learning how do you get rid of the side effects of arvs is essential for maintaining treatment adherence and a high quality of life while living with HIV.